ASCO 2017: Identifying and Targeting Genetic Drivers in Rare Genitourinary Cancer Types
Chicago, IL (UroToday.com) Dr. Sonpavde gave a summary of 3 posters: 4516 – Dr. Eric Jonasch, 4517 – Dr. Sumanta K. Pal, and 4518 – Dr. Simon Rodney. The first poster (4516) was a Phase II study of pazopanib in patients with von Hippel-Lindau disease. Dr. Sonpavde gave a brief background on VHL disease. This disease is a mutation of the the VHL tumor suppressor gene. It is a rare autosomal dominant disease with a prevalence of 1:35000-40000.
ASCO GU: Evaluation of Sexual Function on a Randomized Trial of a Prostate Rectal Spacer
Orlando, Florida USA (UroToday.com) A phase III trial was performed using an absorbable hydrogel (SpaceOAR System) to provide space between the prostate and rectum for men undergoing dose-escalated (to 79.2 Gy IMRT) prostate radiation therapy.
ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Medical Oncology - Session Highlights
Orlando, Florida USA (UroToday.com) In this session, Dr. Brugarolas reviewed the past year’s literature on renal cell carcinoma (RCC) from the medical oncology perspective. He highlighted two adjuvant studies (S-TRAC and ASSURE), Checkmate 025, METEOR, and a first-in-class HIF2α inhibitor trial.
ASCO GU 2017: Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicenter prospective GETUG trial. - Session Highlights
Orlando, Florida USA (UroToday.com) At the genitourinary cancer symposium this year, Christine Chevreau presented the benefit of high dose chemotherapy using the TICE regimen with drug monitoring in patients with advanced germ cell tumors.
ASCO GU 2017: 111- A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT). - Session Highlights
Orlando, Florida USA (UroToday.com) At this years genitourinary cancer symposium Robert Huddart presented the possibility of reducing chemotherapy burden to non-seminoma testis cancer without reducing oncologic efficacy. He presented that 1 cycle of bleomycin, etopiside and cisplatin (BEP) in high risk, stage 1 non-seminoma germ cell tumor (NSGCT) may be comparable to 2 cycles of BEP if a higher dose of etopiside is used.
ASCO GU 2017: Dacomitinib (Daco) induction therapy for locally advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): An open label, single-arm, phase II study. - Session Highlights
Orlando, Florida USA (UroToday.com) Andrea Necchi presented an exciting abstract at this year’s genitourinary cancer symposium expanding targeted therapy with use of daconatinib to penile squamous cell carcinoma. Patients with advanced disease and significant burden generally do poor in penile cancer. Therefore there is a need for further investigation in this rare disease. Dacomatinib is an irreversible TKI of human EGFR/HER1, HER2 and HER4. Necchi presented a phase 2 study (NCT01728233) of daconatinib (45mg daily) on patients with squamous cell histology, and clinical stage N2-3 or M1 disease and have not received prior chemotherapy.
ASCO GU 2017: Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. - Session Highlights
Orlando, Florida USA (UroToday.com) There was much discussion and excitement at this year’s genitourinary cancer symposium regarding the ability of genomic classifiers to predict response to neoadjuvant chemotherapy. Through a fantastic demonstration of collaboration, molecular subtypes in bladder cancer based on gene expression have been widely accepted.